ATE429450T1 - Chimärische dr4 antikörper und ihre verwendung - Google Patents

Chimärische dr4 antikörper und ihre verwendung

Info

Publication number
ATE429450T1
ATE429450T1 AT00937844T AT00937844T ATE429450T1 AT E429450 T1 ATE429450 T1 AT E429450T1 AT 00937844 T AT00937844 T AT 00937844T AT 00937844 T AT00937844 T AT 00937844T AT E429450 T1 ATE429450 T1 AT E429450T1
Authority
AT
Austria
Prior art keywords
antibodies
chimeric
kits
diagnosis
articles
Prior art date
Application number
AT00937844T
Other languages
English (en)
Inventor
Avi Ashkenazi
Anan Chuntharapai
Kelly Dodge
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE429450T1 publication Critical patent/ATE429450T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00937844T 1999-05-28 2000-05-25 Chimärische dr4 antikörper und ihre verwendung ATE429450T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32287599A 1999-05-28 1999-05-28
PCT/US2000/014599 WO2000073349A1 (en) 1999-05-28 2000-05-25 Dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE429450T1 true ATE429450T1 (de) 2009-05-15

Family

ID=23256824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00937844T ATE429450T1 (de) 1999-05-28 2000-05-25 Chimärische dr4 antikörper und ihre verwendung

Country Status (12)

Country Link
EP (2) EP1181319B1 (de)
JP (1) JP4589586B2 (de)
AT (1) ATE429450T1 (de)
AU (3) AU781952B2 (de)
CA (1) CA2374599A1 (de)
CY (1) CY1109151T1 (de)
DE (1) DE60042066D1 (de)
DK (1) DK1181319T3 (de)
ES (1) ES2325305T3 (de)
IL (1) IL146448A0 (de)
PT (1) PT1181319E (de)
WO (1) WO2000073349A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337795A (en) 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
WO2000066156A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
DK1181319T3 (da) * 1999-05-28 2009-08-17 Genentech Inc Kimære DR4-antistoffer og anvendelser deraf
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
JP3665316B2 (ja) * 2001-05-18 2005-06-29 麒麟麦酒株式会社 抗ｔｒａｉｌ−ｒ抗体
DK1572874T3 (da) * 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
EP1409544B1 (de) * 2001-07-03 2009-06-17 Genentech, Inc. Humane dr4-antikörper und deren anwendungen
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
BRPI0510886A (pt) * 2004-06-18 2007-12-26 Genentech Inc método para aumentar a apoptose ou a citotoxicidade em células de mamìferos
BRPI0513639A (pt) 2004-08-06 2008-05-13 Genentech Inc métodos de previsão da sensibilidade, métodos de indução da apoptose e métodos de tratamento de disfunção em mamìferos e de cáncer
CA2575152A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1846034A4 (de) 2005-02-02 2010-11-10 Uab Research Foundation Mittel und verfahren zur reduktion des widerstands gegen apoptose-induzierende todesrezeptor-agonisten
CN101287990B (zh) 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
EP2132312B1 (de) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Konstrukte und bibliotheken mit antikörper-surrogat-leichtkettensequenzen
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
EP2736928B1 (de) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Gegen erbb3-gerichtete sur-bindende proteine
WO2013096828A1 (en) * 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0626012B1 (de) 1992-02-11 2003-07-09 Cell Genesys, Inc. Erzielen von homozygotem durch zielgerichtete genetische ereignisse
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
ES2293682T5 (es) * 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
IL137176A0 (en) * 1998-01-26 2001-07-24 Genentech Inc Antibodies to 4dr and uses thereof
EP1086138B1 (de) * 1998-06-12 2009-09-23 Genentech, Inc. Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
DK1181319T3 (da) * 1999-05-28 2009-08-17 Genentech Inc Kimære DR4-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
EP2213302A3 (de) 2010-11-03
ES2325305T3 (es) 2009-09-01
JP4589586B2 (ja) 2010-12-01
AU2005201915A1 (en) 2005-06-02
CY1109151T1 (el) 2014-07-02
EP2213302A2 (de) 2010-08-04
AU2009201670A1 (en) 2009-05-21
AU781952B2 (en) 2005-06-23
WO2000073349A1 (en) 2000-12-07
WO2000073349A9 (en) 2002-05-10
EP1181319B1 (de) 2009-04-22
AU5296700A (en) 2000-12-18
JP2003503017A (ja) 2003-01-28
PT1181319E (pt) 2009-07-14
DK1181319T3 (da) 2009-08-17
DE60042066D1 (de) 2009-06-04
EP1181319A1 (de) 2002-02-27
IL146448A0 (en) 2002-07-25
CA2374599A1 (en) 2000-12-07
AU2005201915B2 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
WO2004011611A3 (en) Taci antibodies and uses thereof
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
ATE252578T1 (de) 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
ATE239797T1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
ATE325789T1 (de) Aminocyclohexylether-verbindungen und deren verwendung
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE69814563D1 (de) Pyrrolo-(3,2-b)pyridine und ihre Verwendung als 5-HT1F Agonisten
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ATE528392T1 (de) Neues protein und dessen dns
ATE263139T1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie
DE59706692D1 (de) Konjugat, geeignet zur bindung von substanzen
DE3767504D1 (de) Tetrahydrobenz(c,d)indol-derivate, ihre salze, verfahren zur herstellung, verwendung als arzneimittel, ihre zusammensetzungen und zwischenprodukte.
DE69926997D1 (de) Blutverträgliche zusammensetzung und medizinische vorrichtung unter verwendung derselben

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181319

Country of ref document: EP